Decitabine

Overview
Decitabine (trade name Dacogen), or 5-aza-2'-deoxycytidine, is indicated for treatment of patients with myelodysplastic syndrome (MDS), including previously treated and untreated, de novo, and secondary MDS of all FAB subtypes and Intermediate-1, Intermediate-2, and High-Risk IPSS groups. It functions in the same way as 5-Azacytidine.

Basic information

 * Trade Name: Dacogen
 * Generic Name: decitabine
 * FDA approved: May 2, 2006
 * Classification: demethylating agent
 * Manufacturer: MGI Pharma